APP Pharmaceuticals Acquires Three Products from Nexus

Published: May 23, 2012

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, LLC, a Fresenius Kabi Company, today announced it has acquired three products from Nexus Pharmaceuticals, Inc. Under terms of the agreement APP takes complete ownership of the products and becomes the Abbreviated New Drug Application (ANDA) holder for Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic Acid Injection.

Back to news